<DOC>
	<DOCNO>NCT02912884</DOCNO>
	<brief_summary>Myeloproliferative neoplasm ( MPN ) Polycythemia Vera ( PV ) , Essential Thrombocythaemia ( ET ) rare clonal myeloid neoplasms associate increase risk venous arterial thrombosis . Thrombotic complication main determinant morbidity less extend mortality . Routine haemostasis analysis ( TP , aPTT ) usually normal useless demonstrate hypercoagulable state . However , previous evidence suggest global coagulation test thrombin generation thromboelastometry able detect sign procoagulant imbalance MPN . Similarly , current data seem demonstrate fibrin clot property ( clot permeability , turbidimetry , clot lysis time ) property alter suggest hypercoagulable state . Goals PV ET treatment control blood count reduce risk thrombotic event . Moreover , new drug Janus Kinase Inhibitors ( JAKi ) recently license PV investigation clinical trial ET . It currently unknown treatment use ET PV , especially JAKi able modify hypercoagulable state observe disease , difference drug . To evaluate impact MPN treatment prothrombotic haemostatic profile , propose evaluate global coagulation fibrin clot property MPN , depend treatment .</brief_summary>
	<brief_title>Treatment Polycythaemia Vera Essential Thrombocythaemia : Influence Clot Structure</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>All men woman , old 18 year , diagnosis PV ET ( primary secondary ) accord 2008 World Health Organization ( WHO ) classification . Lack participant 's consent ; Concomitant treatment anticoagulant drug ( antivitamin K , heparin direct oral anticoagulant drug ) ; Active cancer nonmelanoma skin cancer ( defined cancer diagnosis &lt; 5 year treatment &lt; 2 year ) ; Recent infection ( &lt; 30d ) ; Recent surgery ( &lt; 30d ) ; Recent hospitalization ( &lt; 30d ) ; Recent thromboembolic cardiovascular event ( &lt; 3m ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>